B2B SaaS Provider · B2C Consumer App / Platform · vs · B2C Consumer App / Platform
Doctolib vs Hims & Hers
Structured technology and market comparison · 2026
Direct Feature Comparison
Doctolib · vs · Hims & HersHealthcare booking and practice software platform for providers and patients.
Consumer telehealth platform with subscription-based treatment and fulfilment.
Analyze all overlapping signals and tech stacks for Doctolib and Hims & Hers
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Doctolib and Hims & Hers?
When comparing Doctolib and Hims & Hers, both platforms operate within the Conversational AI & Chatbots and B2C Consumer App / Platform ecosystem. Doctolib is positioned as Healthcare booking and practice software platform for providers and patients, whereas Hims & Hers focuses on Consumer telehealth platform with subscription-based treatment and fulfilment. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Doctolib and Hims & Hers?
When evaluating Doctolib and Hims & Hers, enterprise buyers also consider other platforms in Conversational AI & Chatbots and B2C Consumer App / Platform. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Doctolib and Hims & Hers compare?
Doctolib is headquartered in FR (founded in 2013) with 1,001–5,000 employees. Hims & Hers is based in US (founded in 2017) with 1,001–5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Doctolib vs Hims & Hers
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Doctolib
Recent Signals
- ·Trending Topics (DACH/CEE Innovation & Tech)AI Investment
Nvidia invests in Doctolib, Pigment, Genesis AI, Entalpic
European tech startups raised €15.8 billion in September, nearly five times August's €3.2 billion, with the UK attracting the largest share (46%). Mega-deals included Mistral's €3 billion Series D and Nscale's $3.36 billion convertible notes; even excluding these, funding tripled month-over-month. Nvidia continued its European expansion by announcing minority investments in four French startups (Doctolib, Genesis AI, Pigment, Entalpic) and five UK startups (Boltz, Foresight, Hiverge, Prima Mente, Riverlane), as part of nearly €9 billion in European commitments. CEO Jensen Huang also announced a $250 million compute donation to UK AI safety and research. Critics question circular financing, while Huang advocates continued dialogue with Chinese AI firms. These moves follow Nvidia's recent agreement to acquire Hugging Face for about $12.9 billion.
- European startups raised €15.8 billion in September, nearly five times August's €3.2 billion.
- Nvidia announced minority investments in four French (Doctolib, Genesis AI, Pigment, Entalpic) and five UK (Boltz, Foresight, Hiverge, Prima Mente, Riverlane) startups, with total European commitment near €9 billion.
- Mistral raised €3 billion in Series D at a valuation over €21 billion, the largest equity round for a European tech company.
- ·Trending Topics (DACH/CEE Innovation & Tech)AI
Nvidia Invests in Four French Tech Companies
Nvidia has announced investments in four French technology companies during Jensen Huang's visit to Paris. The companies are Doctolib, a healthcare appointment platform; Genesis AI, a robotics startup; Pigment, a financial planning software maker; and Entalpic, a materials research startup. The deals are minority stakes, but the specific amounts and equity sizes were not disclosed. Nvidia's investment in Doctolib is intended to support its development of AI agents and a digital health companion. This move is part of Nvidia's broader commitment of nearly $10 billion to Europe's tech ecosystem, with plans to announce an additional $2 billion in European deals within a week. The investments have drawn criticism over potential circular financing, where AI firms use the funds to buy Nvidia chips, but Huang rejects these claims.
- Nvidia invests in Doctolib, Genesis AI, Pigment, and Entalpic.
- The investments are minority stakes; amounts undisclosed.
- Investment in Doctolib supports its AI agent and health companion work.
Hims & Hers
Recent Signals
- ·PR Newswire: Advertising & MarketingPrivacy
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Robbins Geller Rudman & Dowd LLP announces a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged violations of the Securities Exchange Act. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead plaintiff appointment. The lawsuit follows an FTC complaint alleging Hims & Hers shared sensitive health information with third-party advertising platforms like Meta and Snap, and misled consumers about billing. The stock dropped nearly 15% upon the FTC news. Lead plaintiff process outlined under the Private Securities Litigation Reform Act.
- FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms.
- Hims & Hers stock declined nearly 15% following the FTC announcement.
- Robbins Geller Rudman & Dowd LLP filed a class action lawsuit (Velanki v. Hims & Hers Health, Inc.) in the Northern District of California.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for Hims & Hers (2026-08-10)
Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, and six-month revenue of $1.36 billion (+20% YoY), driven by strong expansion in the Hers brand and international growth from acquisitions including Eucalyptus. However, the company experienced a GAAP net loss of $86.3 million for Q2 2026 (compared to net income of $42.5 million in Q2 2025), primarily impacted by a strategic transition in its U.S. GLP-1 weight loss business, non-recurring restructuring charges, increased fulfillment costs from shorter shipping cadences, and a $60 million FTC legal contingency accrual.
- Q2 2026 total revenue reached $753.21 million (+38% YoY) with ending subscribers expanding 19% YoY to 2.89 million.
- GAAP net loss was $86.29 million for Q2 2026, down from net income of $42.51 million in Q2 2025, while Adjusted EBITDA stood at $60.32 million.
- Recorded a $60.0 million legal contingency accrual related to an FTC and multi-state consumer protection lawsuit regarding subscription and cancellation practices.
- ·PR Newswire: Technology NewsPrivacy
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms (Snap, Meta) and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
- Class action lawsuit filed; lead plaintiff deadline is November 2, 2026.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Doctolib and Hims & Hers share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks